

**AMENDMENT**

**In the claims:**

Please amend the claims as indicated below.

1. (Amended) A method of enhancing migration of ~~CaR~~calcium-sensing receptor expressing cells to a specific site in a subject, comprising:

locally administering to a specific site in a subject in need of such treatment a nonCa<sup>++</sup> ~~CaR~~calcium-sensing receptor agonist in an amount effective to enhance migration of ~~CaR~~calcium-sensing receptor expressing cells to the specific site in the subject.

2.-9. (Canceled)

10. (Amended) A method of inhibiting migration of ~~CaR~~calcium-sensing receptor expressing cells to a specific site in a subject, comprising:

locally administering to a specific site in a subject in need of such treatment a ~~CaR~~calcium-sensing receptor antagonist in an amount effective to inhibit migration of ~~CaR~~calcium-sensing receptor expressing cells to the specific site in the subject.

11.-84. (Canceled)

85. (Amended) The method of claim 1, wherein the ~~CaR~~calcium-sensing receptor expressing cells are hematopoietic cells.

86. (Previously Presented) The method of claim 2, wherein the hematopoietic cells are hematopoietic progenitor cells.

87. (Amended) The method of claim 1, wherein the ~~CaR~~calcium-sensing receptor expressing cells are neural cells.

88. (Amended) The method of claim 1, wherein the ~~CaR~~calcium-sensing receptor expressing cells are epithelial cells.

89. (Amended) The method of claim 1, wherein the ~~CaR~~calcium-sensing receptor expressing cells are mesenchymal cells.

90. (Amended) The method of claim 1, wherein the ~~CaR~~calcium-sensing receptor expressing cells are endothelial cells.

91. (Amended) The method of claim 1, wherein the nonCa<sup>++</sup> ~~CaR~~calcium-sensing receptor agonist is NPS R-467.

92. (Amended) The method of claim 1, wherein the nonCa<sup>++</sup> ~~CaR~~calcium-sensing receptor agonist is NPS S-467.

93. (Previously Presented) The method of claim 10, wherein the specific site is a site of inflammation.

94. (Amended) The method of claim 93, further comprising co-administering a non-~~CaR~~-calcium-sensing receptor antagonist that inhibits migration of immune cells to the site of inflammation in the subject.

95. (Amended) The method of claim 94, wherein the non-~~CaR~~-calcium-sensing receptor antagonist is an antiinflammatory agent.

96. (Previously Presented) The method of claim 10, wherein the subject has an autoimmune disease.

97. (Previously Presented) The method of claim 96, wherein the autoimmune disease is rheumatoid arthritis, uveitis, insulin-dependent diabetes mellitus, hemolytic anemias, rheumatic fever, Crohn's disease, Guillain-Bane syndrome, psoriasis, thyroiditis, Graves' disease, myasthenia gravis, glomerulonephritis, autoimmune hepatitis, or systemic lupus erythematosus.

98. (Previously Presented) The method of claim 10, wherein the subject has an abscess, a transplant, an implant, atherosclerosis, or myocarditis.

99. (Amended) The method of claim 10, wherein the ~~CaR~~-calcium-sensing receptor expressing cells are hematopoietic cells.

100. (Previously Presented) The method of claim 99, wherein the hematopoietic cells are hematopoietic progenitor cells.

101. (Amended) The method of claim 10, wherein the ~~CaR~~-calcium-sensing receptor expressing cells are neural cells.

102. (Amended) The method of claim 10, wherein the ~~CaR~~-calcium-sensing receptor expressing cells are epithelial cells.

103. (Amended) The method of claim 10, wherein the ~~CaR~~-calcium-sensing receptor expressing cells are mesenchymal cells.

104. (Amended) The method of claim 10, wherein the ~~CaR~~-calcium-sensing receptor expressing cells are endothelial cells.

105. (Amended) The method according to any of claims 10 or 93-104, wherein the ~~CaR~~-calcium-sensing receptor antagonist is NPS-2143.